Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.82 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.82 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.82 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.82 |
| ▸ | MEN1 | O00255 | 1/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.65 |
| ▸ | PKM | P14618 | 1/20 | 0.64 |
| ▸ | POLB | P06746 | 2/20 | 0.62 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 4/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 3/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | HPGD | P15428 | 2/20 | 0.48 |
| ▸ | THRB | P10828 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2521926 | 0.88 | SMN1; SMN2 (0.80) | ALDH1A1SMN1; SMN2CYP1A2CYP2C19MEN1 | |
| SCHEMBL9941742 | 0.87 | ALDH1A1 (0.82) | ALDH1A1SMN1; SMN2CYP1A2CYP2C19MEN1 | |
| SCHEMBL9938533 | 0.83 | ALDH1A1 (0.69) | ALDH1A1SMN1; SMN2CYP1A2CYP2C19MEN1 | |
| SCHEMBL9941025 | 0.81 | ALDH1A1 (0.66) | ALDH1A1SMN1; SMN2CYP1A2CYP2C19MEN1 | |
| SCHEMBL29256111 | 0.80 | ALDH1A1 (0.70) | ALDH1A1SMN1; SMN2CYP1A2CYP2C19MEN1 | |
| SCHEMBL13968596 | 0.79 | POLB (0.64) | ALDH1A1SMN1; SMN2CYP1A2CYP2C19MEN1 | |
| SCHEMBL4485648 | 0.77 | POLB (1.00) | ALDH1A1SMN1; SMN2CYP1A2CYP2C19MEN1 | |
| SCHEMBL2526216 | 0.76 | ALDH1A1 (0.64) | ALDH1A1SMN1; SMN2CYP1A2CYP2C19MEN1 | |
| SCHEMBL17340784 | 0.76 | ALDH1A1 (0.60) | ALDH1A1SMN1; SMN2CYP1A2CYP2C19MEN1 | |
| SCHEMBL2534800 | 0.74 | SMN1; SMN2 (0.62) | ALDH1A1SMN1; SMN2CYP1A2CYP2C19MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117279917-A | Piperazine derivatives and their use in medicine | 成都百裕制药股份有限公司 | 2023-12-22 | — | — | CN | disclosed |
| EP-1917262-B1 | PIPERIDINE AND PIPERAZINE DERIVATIVES AS P2X3 ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2011-12-14 | — | — | EP | disclosed |
| US-7491821-B2 | 2-(4-fluorophenyl)-4-propyl-oxazole-5-carboxylic acid {2-[4-(6-aminopyridin-2-yl)-piperazin-1-yl]-1-methyl-ethyl}amide; purinergic receptor antagonists, analgesics; urogenital, gastointestinal and respiratory system disorders | ROCHE PALO ALTO LLC (US) | 2009-02-17 | — | — | US | disclosed |
| EP-1917262-A1 | PIPERIDINE AND PIPERAZINE DERIVATIVES AS P2X3 ANTAGONISTS | F.HOFFMANN-LA ROCHE AG (CH) | 2008-05-07 | — | — | EP | disclosed |
| WO-2007020194-A1 | PIPERIDINE AND PIPERAZINE DERIVATIVES AS P2X3 ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-02-22 | — | — | WO | disclosed |
| US-20070037974-A1 | Inhibitors of P2X3 | ROCHE PALO ALTO LLC | 2007-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070037974-A1 | Inhibitors of P2X3 | P2RX3, P2RX4, P2RX5 | ALDH1A1 2159/4885SMN1; SMN2 3624/4885CYP1A2 1965/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.